We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Benefits of Intensive Glycemic Control in Elderly Patients With Type 2 Diabetes

This study is currently recruiting participants.
Verified June 2010 by Taipei Veterans General Hospital, Taiwan
Sponsor:
ClinicalTrials.gov Identifier:
NCT00850798
First Posted: February 25, 2009
Last Update Posted: July 26, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by:
Taipei Veterans General Hospital, Taiwan
  Purpose

Aims/hypothesis:

Populations worldwide are aging and type 2 diabetes is common in individuals aged >80 years. The important issue that needs to be considered is whether tight glycemic control is benefits for elderly patients with type 2 diabetes. The benefits of intensive glucose control remain uncertain for the heterogeneous population of older diabetic patients due to a lack of clinical trial data evaluating the benefits of long-term intensive glucose control in older patients. This study is designed to provide reliable evidence on the balance of benefits and risks conferred by intensive glucose control in elderly patients with type 2 diabetes Methods: This is a prospective, randomized, open-labeled, controlled design to assess the benefits of treating elderly patients with type 2 diabetes. The study will include 208 elderly patients with type 2 diabetes and follow-up for 5 years. Eligible patients are randomized to receive intensive (A1C <7.0%) or conservative (A1C around 8.0%) glycemic control. The primary study outcomes are a composite of macrovascular events and a composite of microvascular events, considered both jointly and separately. The secondary outcomes are death from any cause, death from cardiovascular causes, total coronary events, total cerebrovascular events, heart failure, peripheral vascular events, all cardiovascular events, and hospitalization for 24 hours or more.

Expected results: This study is designed to provide reliable evidence on the balance of benefits and risks conferred by intensive and conservative glucose control in elderly patients with type 2 diabetes. Once completed, this trial will clearly influence the management of elderly patients with type 2 diabetes, regardless of the results.


Condition Intervention
Type 2 Diabetes Drug: Intensive glycemic control Drug: Conservative glycemic control

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Taipei Veterans General Hospital, Taiwan:

Primary Outcome Measures:
  • The primary study outcomes are a composite of macrovascular events and a composite of microvascular events, considered both jointly and separately. [ Time Frame: Every 6 months and up to 5 years ]

Secondary Outcome Measures:
  • The secondary outcomes are death from any cause, disability from any cause, total coronary events, total cerebrovascular events, heart failure, peripheral vascular events, all cardiovascular events, and hospitalization for 24 hours or more. [ Time Frame: Every 6 months and upto 5 years ]

Estimated Enrollment: 208
Study Start Date: February 2009
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Fasting plasma glucose (mg/dL) 90 to 130 Glycated hemoglobin (%) 6.0 to 7.0
Drug: Intensive glycemic control
Intensive glycemic control
Active Comparator: 2
Fasting plasma glucose (mg/dL) 90 to 180 Glycated hemoglobin (%) 7.0 to 9.0
Drug: Conservative glycemic control
OADs and insulin

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   80 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women aged ≥80 years at time of randomization.There is no upper age limit.
  • Be able to walk by themselves
  • They had their first diagnosis of type 2 diabetes mellitus at age 30 years or older.

Exclusion Criteria:

  • Known advanced diabetic complications (such as proliferative retinopathy, chronic kidney disease stage IV or above).
  • Overt clinical congestive heart failure (CHF) requiring treatment with a diuretic or ACE inhibitor.
  • Previous documented cerebral or subarachnoid haemorrhage in the last 6 months
  • Condition expected to severely limit survival
  • Clinical diagnosis of dementia
  • Resident in a nursing home
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00850798


Contacts
Contact: Harn-Shen Chen, MD, PhD 886-2-28757515 chenhs@vghtpe.gov.tw
Contact: Hong-Da Lin, MD. 886-2-28757012 hdlin@vghtpe.gov.tw

Locations
Taiwan
Chen-Hsen Lee Recruiting
Taipei, Taiwan, 11217
Contact: Harn-Shen Chen, MD, PhD         
Sponsors and Collaborators
Taipei Veterans General Hospital, Taiwan
  More Information

Responsible Party: Chen-Hsen Lee, Chairman, Institutional Review Board, Taipei Veterans General Hospital,Taiwan
ClinicalTrials.gov Identifier: NCT00850798     History of Changes
Other Study ID Numbers: VGHIRB 97-12-04
First Submitted: February 23, 2009
First Posted: February 25, 2009
Last Update Posted: July 26, 2010
Last Verified: June 2010

Keywords provided by Taipei Veterans General Hospital, Taiwan:
Type 2 diabetes
Elder patients
Glycemic control
Men or women aged ≥80 years at time of randomization. There is no upper age limit.
Be able to walk by themselves
They had their first diagnosis of type 2 diabetes mellitus at age 30 years or older.

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases